

# BIOLOGICAL TREATMENTS FOR PSORIASIS: FINANCIAL IMPACT OF DOSE MODIFICATION

CP-142

E. Rios-Sanchez<sup>1</sup>, F. Fenix-Caballero<sup>1</sup>, M.J. Gandara-LadrondeGuevara<sup>1</sup>, J.C. Armario-Hita<sup>2</sup>, C. Palomo-Palomo<sup>1</sup>, J. Diaz-Navarro<sup>1</sup>, J.M. Borrero-Rubio<sup>1</sup>  
<sup>1</sup> Puerto Real University Hospital. Pharmacy. Puerto Real (Cadiz), Spain. <sup>2</sup> Puerto Real University Hospital. Dermatology. Puerto Real (Cadiz), Spain.

## BACKGROUND

Biological therapies are effective treatments for chronic plaque psoriasis. Label doses are used at the beginning of the treatment, but they tend to be reduced in clinical practice when the drug has demonstrated sustained effectiveness.

## PURPOSE

Main objective

• Assess the average cost per patient of each anti-TNF drug based on its prescribed doses

Secondary objectives

• Estimate the annual costs per responder  
 • Estimate the incremental cost

## MATERIAL AND METHOD

Cross-sectional observational study was carried out from January to June 2014. Patients with psoriasis and who had received biologic therapy for at least six months were included.

Effectiveness endpoint: proportion of patients with at least 75% improvement in the psoriasis area-and-severity index (PASI75).

Mean prescribed doses of each biological drug were calculated and translated into a percentage of the label doses.

The average cost per patient of each drug was assessed with the mean prescribed doses (real costs, RC) .  
 The theoretical costs (TC) were estimated based on the label dose drugs.  
 The incremental cost (IC) was calculated by comparing the TC vs. RC.  
 For the purpose of calculating the annual costs, the RC of six-month treatment were extrapolated.

This study was performed from the pharmacoeconomic perspective of the hospital.

## RESULTS

	ADALIMUMAB (N=45)	ETANERCEPT (N=44)	USTEKINUMAB (N=32)	INFLIXIMAB (N=22)
Cost per patient based on its prescribed doses	4.777,06€	4.722,38€	5.337,34€	6.546,82€
Cost per patient based on its label doses	6.245,72€	5.788,19€	5.689,02€	6.546,82€
Proportion of patients with PASI75	98%	90%	90%	100%
Estimated annual real costs per responder	9.771,27€	10.389,24€	11.778,95€	13.093,65€
Estimated TC	12.491,44€	11.576,38€	11.378,05€	13.093,65€
Estimated RC	9.554,13€	9.444,76€	10.674,68€	13.093,65€
IC	-2.937,30€	-2.131,62€	-703,36€	0€

## CONCLUSION

- ▣ The average RC of each biological drug was lower than TC, except for Infliximab.
- ▣ Both the annual RC and the IC of Adalimumab were better than the other drugs, followed by Etanercept and Ustekinumab. Infliximab did not allow dosage reduction.
- ▣ Reducing doses of biological therapies permits the minimisation costs while maintaining clinical effectiveness.